Indicated for overactive bladder to manage urinary urgency and support bladder capacity.
Mechanism of Action
Mirabegron stimulates beta-3 adrenergic receptors in the detrusor muscle of the bladder. This induces muscle relaxation during the storage phase, increasing bladder capacity and delaying the urge to urinate.
Route of Administration
Oral
Onset Time
4–8 weeks
Duration
24 hours
Contraindications
Severe uncontrolled hypertension, Hypersensitivity to mirabegron
Severe Adverse Events
Severe hypertension, Angioedema, Urinary retention — requires immediate medical attention
Information related to Myrbetriq is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
